Ibogaine Safety Guide

Ibogaine Safety Guide: What Every Patient Needs to Know Before Treatment

Ibogaine is one of the most powerful therapeutic medicines ever studied — and one of the few substances that carries enough cardiovascular risk to require clinical-grade medical supervision. This guide covers everything a patient needs to understand before pursuing ibogaine treatment: the real risks, the safety protocols that reduce them, the medications that must be stopped, and how to verify that a clinic is operating to the standard your safety requires.

We publish this guide because accurate safety information is rare in the ibogaine space. Too many sources either catastrophize the risks to the point of discouraging legitimate patients, or minimize them in ways that put people in danger. The truth is more useful: the risk is far lower in a properly supervised clinical setting. It is genuinely dangerous without one.

The Core Safety Concern: QT Prolongation

Ibogaine prolongs the QT interval — the time it takes for the heart’s electrical system to recharge between beats. In patients with pre-existing cardiac conditions, structural heart abnormalities, electrolyte imbalances, or certain medication interactions, this QT prolongation can trigger potentially fatal cardiac arrhythmias, including torsades de pointes and ventricular fibrillation.

This is the mechanism behind most documented ibogaine-related deaths. Reviews of adverse cardiac events in ibogaine treatment have involved one or more of the following:

• Failure to perform pre-treatment cardiac screening
• Contraindicated medications not identified or cleared
• Electrolyte imbalances not corrected before treatment
• Treating patients with absolute cardiac contraindications

In properly screened patients at clinics with appropriate medical infrastructure, ibogaine-related cardiac events are exceedingly rare. The risk is real but manageable — and manageable risks managed well are not reasons to avoid treatment. They are reasons to choose the right setting.

Required Pre-Treatment Medical Screening

Every reputable ibogaine clinic requires the following before admission:

What the clinic will ask you for

• A 12-lead EKG/ECG, blood pressure and heart rate, plus a cardiology consultation if the EKG or your family history calls for one
• Bloodwork: complete blood count, comprehensive metabolic panel (liver enzymes ALT and AST, kidney function, and potassium, magnesium and sodium) and liver function tests, because ibogaine is metabolized in the liver
• A drug screen and your substance-use history, including exact doses and last-use dates
• Your complete medication list, including over-the-counter drugs and supplements
• Psychiatric history, including diagnoses, current symptoms and any hospitalizations, and your family medical history

Absolute Contraindications

The following conditions make ibogaine treatment unsafe regardless of other factors. Patients with these contraindications should not receive ibogaine:

• Prolonged QTc interval (>450ms men / >470ms women)
• Cardiac arrhythmia history — including atrial fibrillation, ventricular tachycardia, WPW syndrome
• Significant structural heart disease — including heart failure, cardiomyopathy, significant valvular disease
• Severe liver disease or cirrhosis (Child-Pugh Class B or C)
• Active psychosis or schizophrenia spectrum disorder
• Bipolar I disorder (except in rare cases under specialist supervision)
• Pregnancy
• Cerebellar ataxia

Medication Contraindications

This is one of the most important and most misunderstood areas of ibogaine safety. Many commonly prescribed medications interact dangerously with ibogaine — either by extending QT interval themselves, or by interacting with ibogaine’s metabolism in ways that alter its concentration in the body.

Absolute Medication Contraindications (Do Not Use Ibogaine With These)

• Methadone — significant QT prolongation risk; requires extended taper (typically 4–8 weeks to under 30mg) before ibogaine
• Tramadol — serotonin syndrome and seizure risk
• Lithium — significant QT risk; requires taper and washout
• Most antipsychotics — many are potent QT prolongers (haloperidol, quetiapine, risperidone, olanzapine, aripiprazole)
• Class I and III antiarrhythmics — including amiodarone, flecainide, sotalol
• Citalopram/escitalopram — among the highest QT prolongation risk of the SSRIs
• Cocaine — cardiovascular risk during the ibogaine session; minimum 24–48 hours abstinence required

Medications Requiring Supervised Taper Before Ibogaine

• Buprenorphine/Suboxone — competitive binding at opioid receptors blocks ibogaine’s anti-addiction mechanism; requires taper to low doses (under 2mg) or full cessation under medical supervision, typically 2–4 weeks
• Most SSRIs — serotonergic interactions; generally require 2–4 week taper and washout (fluoxetine requires longer due to long half-life)
• SNRIs — similar to SSRIs; require taper and washout
• Benzodiazepines — long-term benzodiazepine dependence must be addressed carefully before ibogaine; abrupt cessation can cause dangerous withdrawal

Important: Do not stop any medication abruptly without medical supervision. Abrupt cessation of SSRIs, benzodiazepines, or buprenorphine can cause serious withdrawal reactions. The purpose of tapering is both safety and efficacy — not just risk reduction before ibogaine, but appropriate management of the underlying dependency.

If you or someone close to you needs help right now, SAMHSA’s national helpline is free, confidential and staffed 24/7 on 1-800-662-HELP.

If you are still deciding between modalities, our comparison of ibogaine with suboxone and methadone covers how each handles opioid dependence.

What Safe Ibogaine Administration Looks Like

Understanding what a safe clinical setup requires helps patients evaluate clinics more effectively.

Before the Session

• Complete cardiac workup reviewed and cleared by a physician
• All contraindicated medications tapered and at appropriate washout period
• Electrolytes corrected if needed (particularly potassium and magnesium)
• Patient fasted for 6–8 hours
• Baseline vital signs documented

During the Session

• Physician (MD) physically present throughout the 24–36 hour experience
• Continuous EKG cardiac monitoring
• IV access in place for emergency medication administration
• Emergency medications available: atropine (for bradycardia), lidocaine (for arrhythmia), magnesium sulfate
• Oxygen available
• Defibrillator on site
• Regular vital sign checks
• Protocol for hospital transfer documented and rehearsed

After the Session

• Monitoring continues through the acute recovery phase (24–48 hours post-session)
• Continued vital sign monitoring
• Rest, hydration, and nutritional support
• Integration support begins during residential stay

Want a second set of eyes on a clinic’s safety setup? Tell an advisor which clinic you are considering and we will compare it against this checklist with you. Ask an advisor or call or text (866) 435-7057.

The Safety Record in Perspective

Ibogaine has been used in clinical settings for over 30 years. The safety record, when proper protocols are followed, is strong. The adverse event rate at well-run clinics is very low. The substance itself is not inherently more dangerous than many pharmaceuticals with established safety protocols — it is dangerous only when those protocols are absent.

For comparison: opioid withdrawal itself carries mortality risk. The medical management of severe alcohol withdrawal requires ICU-level care. The appropriate comparison is not “ibogaine vs. doing nothing” but “ibogaine in a proper clinical setting vs. the ongoing risk of active addiction.”

The 2024 Stanford study — the largest prospective ibogaine study published to date, though observational rather than controlled — reported no unexpected or serious adverse events in their veteran patient cohort, all of whom received ibogaine under the safety protocol described above. This is not an accident; it is the result of proper screening and clinical infrastructure.

Questions to Ask a Clinic About Safety

1. What cardiac screening do you require, and how recent must it be?
2. Is there a physician on site throughout the ibogaine session?
3. Do you have continuous EKG monitoring during treatment?
4. What emergency medications and equipment do you have on site?
5. What is your protocol if a patient has a cardiac event?
6. What is the nearest hospital and how long does transfer take?
7. Have you ever had a serious adverse event, and what happened?
8. What medications require patients to complete a taper before treatment with you?

A clinic that cannot answer these questions clearly and confidently is not operating to safety standards. Legitimate clinics welcome these questions — they demonstrate that the patient understands what proper care requires.

For Patients Currently on Suboxone or Methadone

This is one of the most common situations we encounter, and it requires special attention.

Buprenorphine (Suboxone/Subutex): You will need to taper to a low dose — typically under 2mg — or complete cessation, under medical supervision, before ibogaine. The taper timeline depends on your current dose and your individual response. Rushing this process risks both withdrawal during the taper and suboptimal ibogaine outcomes. Most reputable clinics want patients at low buprenorphine doses for at least 2 weeks before treatment.

Methadone: More complex due to methadone’s long half-life and its own QT-prolonging properties. You will need to taper to 30mg or below — ideally lower — over weeks to months, under medical supervision, before ibogaine is safe. Patients who have been on high-dose methadone (80mg+) often require 8–12 weeks of taper before ibogaine candidacy.

We walk through this with every patient who contacts us. If you are on either medication and considering ibogaine, contact us for a detailed discussion of your specific situation and timeline.

Ibogaine and the 5-MeO-DMT Combination

Many clinics now offer ibogaine combined with 5-MeO-DMT (the “God Molecule,” derived from the Sonoran Desert toad). This combination is supported by a small but growing body of clinical data, particularly for PTSD and trauma. The 5-MeO-DMT session typically occurs 24–48 hours after the ibogaine session, once the patient has stabilized.

From a safety perspective, 5-MeO-DMT has a much simpler risk profile than ibogaine — it does not carry cardiac risk at clinical doses, and the experience, while intense, is brief (15–45 minutes). The primary safety considerations for the combination involve spacing the sessions appropriately and ensuring the patient is medically stable after ibogaine before proceeding.

Summary: The Safety Checklist

Before committing to any ibogaine clinic:

• ✓ Clinic requires 12-lead EKG before admission
• ✓ Physician is on site (not on call) throughout the session
• ✓ Continuous cardiac monitoring during treatment
• ✓ Emergency medications and defibrillator on site
• ✓ Your complete medication list has been reviewed
• ✓ Any contraindicated medications have been tapered under medical supervision
• ✓ Your electrolytes have been checked and corrected if needed
• ✓ Integration support is included in the program

At Psychedelic Connect, we refer patients only to clinics that meet these standards. Our medical pre-screening guidance is included. Call (866) 435-7057 or complete our consultation form to begin.

Vetted Ibogaine and 5-MeO-DMT providers. psychedelic-connect.com